Nuvalent
preliminary safety profile favorable and consistent with the highly selective sparing design of phase treatment related adverse events in patient all treated patients no no treatment related no aes leading to dose reduction or discontinuation no treatment related fatigue alt increased ast increased myalgia grade grade any grade grade ses alt aint as aspartate source a doe serous ses i | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
April 2024
Slide
35 of 42
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
preliminary safety profile favorable and consistent with alk selective sparing design of phase treatment related adverse events in patients all treated patients has not been identified transient asymptomatic grade increase infrequent requiring dose modification discontinued due to dose reduced due to overall avoiding related any alt increased ast increased i nausea constipation fatigue peripheral edema grade grade grade any grade reduced dose for source lin a creatinine dose limiting toxicity treatment related adverse event intolerable at from grade alt ast elevation grade nausea cognitive disturbance grade elevation grade treatment continues at the | Nuvalent
Investor Presentation
February 2024
preliminary safety profile favorable and consistent with the highly selective sparing design of phase no no treatment related no aes leading to dose reduction or discontinuation no treatment related dizziness treatment related adverse events in patient all treated patients nausea alt increased ast increased myalgia grade grade grade any grade data as for patients treated by adverse event alt alanine ast aspartate dose limiting including source a toxicity | Nuvalent
Investor Presentation
February 2024
preliminary safety profile favorable and consistent with alk selective sparing design of phase treatment related adverse events in patients all treated patients has not been identified transient asymptomatic grade increase infrequent requiring dose modification discontinued due to dose reduced due to overall avoiding related any alt increased ast increased nausea constipation fatigue peripheral edema grade grade grade any grade resulting in treat resulting in dose reduced dose for source lin grade alt ast elevation grade nausea cognitive disturbance grade elevation grade treatment continues at the city treatment related adverse event at from | Nuvalent
Investor Presentation
January 2024
preliminary safety profile favorable and consistent with the highly selective sparing design of in no no treatment related no aes leading to dose eduction or or discontinuation ion no treatment related dizziness treatment related adverse events in patient all treated patients fatigue alt increased ast increased myalgia grade grade grade any grade data as for patients treated by adverse event alt alanine ast aspartate dose limiting toxicity including source a a | Nuvalent
Related slides by other companies
Chimerix
Investor Presentation
March 2023
safety nausea tam a a a dose modifications discontinuations uncommon and treatment related aes generally grades | Chimerix
Compass Therapeutics
Investor Presentation
May 2022
safety data treatment related grade adverse events | Compass Therapeutics
Oculis
Results
August 2023
overall summary of treatment emergent adverse events | Oculis
AstraZeneca
Investor Day
September 2021
adverse events of special interest | AstraZeneca
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io